{"id":"dasatinib-and-blinatumomab","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Myelosuppression"},{"rate":"20-40%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Headache"},{"rate":"10-30%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1742992","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Dasatinib works by binding to the ATP-binding site of its target kinases, thereby inhibiting their activity. Blinatumomab, on the other hand, binds to CD19 on cancer cells and CD3 on T cells, bringing them together to induce T cell-mediated killing of cancer cells.","oneSentence":"Dasatinib is a tyrosine-kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFRβ, while blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:24.445Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Chronic myeloid leukemia (CML)"}]},"trialDetails":[{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT02143414","phase":"PHASE2","title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-06-30","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":53},{"nctId":"NCT06124157","phase":"PHASE3","title":"A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-30","conditions":"B Acute Lymphoblastic Leukemia","enrollment":222},{"nctId":"NCT06773936","phase":"PHASE2","title":"Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","status":"ENROLLING_BY_INVITATION","sponsor":"SWOG Cancer Research Network","startDate":"2026-05-15","conditions":"Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia","enrollment":55},{"nctId":"NCT06533748","phase":"PHASE2","title":"Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-01-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":128},{"nctId":"NCT04872790","phase":"PHASE1","title":"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-09-02","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia","enrollment":20},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT03595917","phase":"PHASE1","title":"ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML","status":"RECRUITING","sponsor":"Marlise Luskin, MD","startDate":"2018-07-24","conditions":"B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL","enrollment":40},{"nctId":"NCT05192889","phase":"PHASE1, PHASE2","title":"Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-08-25","conditions":"Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia","enrollment":35},{"nctId":"NCT07152041","phase":"PHASE3","title":"Newly-diagnosed Pediatric Ph-positive B-ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-28","conditions":"Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic","enrollment":150},{"nctId":"NCT04329325","phase":"PHASE2","title":"Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-30","conditions":"Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive","enrollment":17},{"nctId":"NCT03318770","phase":"","title":"Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2019-05-10","conditions":"Acute Lymphoblastic Leukemia","enrollment":60},{"nctId":"NCT02744768","phase":"PHASE2","title":"D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2017-05-31","conditions":"Acute Lymphoblastic Leukemia","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":55,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Dasatinib and blinatumomab","genericName":"Dasatinib and blinatumomab","companyName":"Gruppo Italiano Malattie EMatologiche dell'Adulto","companyId":"gruppo-italiano-malattie-ematologiche-dell-adulto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dasatinib is a tyrosine-kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFRβ, while blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3. Used for Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}